CD26 expression is attenuated by TGF-β and SDF-1 autocrine signaling on stromal myofibroblasts in human breast cancers

Yoshihiro Mezawa1 | Yataro Daigo2,3 | Atsushi Takano2,3 | Yohei Miyagi4 | Tomoyuki Yokose5 | Toshinari Yamashita6 | Chikao Morimoto7 | Okio Hino1 | Akira Orimo1

1Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan
2Center for Antibody and Vaccine Therapy, Institute of Medical Science, Research Hospital, The University of Tokyo, Tokyo, Japan
3Department of Medical Oncology and Cancer Center, Shiga University of Medical Science, Otsu, Japan
4Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan
5Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan
6Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
7Department of Therapy Development and Innovation for Immune Disorders and Cancers, Juntendo University, Tokyo, Japan

Correspondence
Akira Orimo, Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Email: aorimo@juntendo.ac.jp

Funding information
Ministry of Education, Culture, Sports, Science and Technology, Japan, Grant/Award Number: 24300332, 25640069, 15K14385 and JP 16H06277

Abstract
Human breast carcinoma-associated fibroblasts (CAFs) increasingly acquire both transforming growth factor-β (TGF-β) and stromal cell-derived factor-1 (SDF-1) signaling in an autocrine fashion during tumor progression. Such signaling mediates activated myofibroblastic and tumor-promoting properties in these fibroblasts. CD26/dipeptidyl peptidase-4 is a serine protease that cleaves various chemokines including SDF-1. Stromal CD26 expression is reportedly undetectable in human skin squamous cell carcinomas. However, whether stromal CD26 expression is also downregulated in human breast cancers and which stromal cells potentially lack CD26 expression remain elusive. To answer these questions, sections prepared from 239 human breast carcinomas were stained with antibodies against CD26 and α-smooth muscle actin (α-SMA), a marker for activated myofibroblasts. We found that tumor-associated stroma involving α-SMA-positive myofibroblasts stained negative or negligible for CD26 in 118 out of 193 (61.1%) tumors, whereas noncancerous stromal regions of the breast showed considerable staining for CD26. This decreased stromal CD26 staining in tumors also tends to be associated with poor outcomes for breast cancer patients. Moreover, we demonstrated that CD26 staining is attenuated on stromal myofibroblasts in human breast cancers. Consistently, CD26 expression is significantly downregulated in cultured CAF myofibroblasts extracted from human breast carcinomas as compared to control human mammary fibroblasts. Inhibition of TGF-β or SDF-1 signaling in CAFs by shRNA clearly upregulated the CD26 expression. Taken together, these findings indicate that CD26 expression is attenuated by TGF-β- and SDF-1-autocrine signaling on stromal myofibroblasts in human mammary carcinomas, and that decreased stromal CD26 expression has potential as a prognostic marker.

KEYWORDS
breast cancer, dipeptidyl peptidase 4, myofibroblasts, stromal cell-derived factor 1, TGF-beta
1  |  INTRODUCTION

Desmoplastic stroma rich in α-smooth muscle actin (α-SMA)-positive myofibroblasts, a hallmark of activated fibroblasts, is frequently observed in various human carcinomas including those of the breast, prostate, pancreas, lung, and colon. In contrast, such myofibroblasts are rarely identified within nontumor stromal regions. Large numbers of myofibroblasts and α-SMA-negative fibroblasts often comprise carcinoma-associated fibroblasts (CAFs) in the tumor-associated stroma.

CAFs rich in myofibroblasts produce multiple growth factors, cytokines, chemokines, and exosomes which influence a wide variety of tumor hallmarks. We and others have previously described that CAF-secreted transforming growth factor-β (TGF-β) and stromal cell-derived factor-1 (SDF-1) promote the growth of aposed carcinoma cells in a paracrine fashion. These stromal cytokines also allow establishment of cross-communicating TGF-β and SDF-1 autocrine signaling by acting on their cognate receptors, resulting in the induction and maintenance of activated, tumor-promoting properties of CAFs without ongoing interaction with tumor cells during tumor progression.

Possible CAF markers including α-SMA, fibroblast activation protein alpha, fibroblast-specific protein-1 (also known as S100A4), tenasin-C, platelet-derived growth factor receptor-α/β, and podoplanin have been identified. Although these CAF markers are useful for predicting the outcomes of some human breast carcinoma cohorts, none fully or exclusively identifies activated tumor-promoting CAFs due to various differences in fibroblast populations, as exemplified by resident fibroblasts and bone-marrow-derived progenitors present in tumors. Therefore, no conventional stromal marker has yet been identified for use in routine prognostic determinations for human carcinomas including those of the breast.

CD26/dipeptidyl peptidase-4 (DPP-4) is expressed by a wide variety of cell types and is involved in T-cell activation, immune regulation, cell adhesion, signal transduction, apoptosis, and so on. Both membrane-bound and soluble forms of CD26 have serine protease activity that preferentially cleaves dipeptides from the N-terminal region of peptides and proteins with a proline or alanine residue in the penultimate position. Stromal CD26 expression has been shown to be remarkably attenuated in human skin and oral squamous cell carcinomas (SCCs). However, whether stromal CD26 expression is commonly downregulated in different cancer types remains unclear. Moreover, the stromal cell types potentially lacking CD26 expression, as well as the molecular mechanisms underlying attenuated stromal CD26 expression, has not as yet been elucidated.

In the present study, we demonstrated that CD26 expression is attenuated via TGF-β and SDF-1 autocrine signaling on stromal myofibroblasts in human breast carcinomas. This downregulated stromal CD26 expression in tumors is associated with poor outcomes for breast cancer patients.

2  |  MATERIALS AND METHODS

2.1  |  Cell culture

Human mammary fibroblasts were extracted from a healthy breast tissue specimen that had been obtained by reduction mammoplasty prior to primary culture and immortalization with human telomerase reverse transcriptase as described previously. Human breast exp-CAF2 cells and the corresponding control human mammary fibroblasts were also employed. These cells were cultured in DMEM high glucose GlutaMAX™ (Gibco) supplemented with 10% fetal bovine serum (FBS) and 1% Pen Strep (100 U/mL penicillin and 100 μg/mL streptomycin) (Gibco). MCF10DCIS.com (DCIS) cells were purchased from Asterand Bioscience. MDA-MB-231 cells were purchased from American Type Culture Collection. These breast cancer cells were cultured in DMEM/F-12, GlutaMAX™ (Gibco) supplemented with 1% PenStrep (Gibco) with 5% FBS (DCIS cells) or 10% FBS (MDA-MB-231 cells).

2.2  |  Immunohistochemistry

The use of formalin-fixed paraffin-embedded (FFPE) tissue specimens of breast cancer in this study was approved by the Jundto University ethics review board. FFPE invasive breast carcinomas were prepared from breast cancer patients who had received either preoperative chemotherapy or hormone therapy. Three-micrometre thick sections were prepared and deparaffinized. The slides were then treated with 0.3% H2O2 in methanol for 20 minutes at room temperature. Antigen retrieval was performed by autoclaving in citrate buffer at pH 6.0 for 20 minutes at 121°C. The slides were incubated with primary antibody at 4°C overnight. Secondary antibody was incubated for 1 hour at room temperature. 3,3′-diaminobenzidine was used as the chromogen followed by hematoxylin counterstaining.

Semiquantification of CD26-positive fibroblasts was performed as follows. Ten different fields on both cancerous and noncancerous regions rich in stroma of the breast were captured per slide using x400 magnification under a microscope. The stromal cells exhibiting a typical fibroblast-like spindle-shape were regarded as “fibroblast-like cells.” Tumor cells, vascular endothelial cells, white blood cells, and adipocytes were also discriminated morphologically. CD26-positive fibroblast-like cells (%) were calculated as the ratio of the number of CD26-positive fibroblast-like cells relative to that of all fibroblast-like cells in cancerous and noncancerous regions of specimens obtained from 10 breast cancer patients.
2.3 Tissue microarray

Tissue microarrays were constructed using 239 formalin-fixed primary breast cancer specimens, as reported previously. Paraffin-embedded tissue sections were obtained from specimens that had been surgically resected at Kanagawa Cancer Center. Individual institutional ethics committees approved this study and the use of all clinical materials. Experiments were performed in accordance with all guidelines and regulations indicated by these committees. The tissue area for sampling was selected based on visual alignment with the corresponding hematoxylin and eosin-stained section on a slide. Several tissue cores (diameter 0.6 mm; height 3-4 mm) taken from a donor tumor block were

![Image](image_url)

**FIGURE 1** Attenuated CD26 staining on stromal myofibroblasts in human breast cancers. A, Hematoxylin and eosin (HE) staining and immunohistochemistry of sections prepared from human breast cancer tissue specimens using anti-CD26 or α-smooth muscle actin (α-SMA) antibodies. CD26+ fibroblast-like cells in a noncancerous region and α-SMA+ myofibroblasts in a cancerous region are indicated by arrows. α-SMA+ pericytes associated with a blood vessel (arrowhead) and α-SMA+ myoepithelial cells surrounding normal mammary glands (asterisks) are also shown. Scale bar, 50 µm. Right column, magnified images of CD26 staining. Scale bar, 20 µm. B, Double immunofluorescence of sections prepared from the human breast tissue specimens. CD26− α-SMA+ myofibroblasts (arrows) in a cancerous region and CD26+ α-SMA− fibroblast-like cells (arrowheads) in a noncancerous region are shown. Scale bar, 30 µm. C, Double immunofluorescence of sections prepared from the noncancerous region of the human breast cancer tissue. CD26+ vimentin+fibroblasts are indicated by arrowheads. Scale bar, 30 µm. D, Quantification of CD26-positive fibroblast-like cell populations in tumor-associated stroma of 10 human breast cancer patients. Human breast tissues including noncancerous and cancerous regions were stained with anti-CD26 antibody. **P < 0.001 by paired t-test. E, Kaplan-Meier plot indicating overall survival of breast cancer patients. Patients were grouped according to the indicated CD26 staining in tumor-associated stroma rich in myofibroblasts (>50% positive for α-SMA staining). The P-value was determined based on the Log-rank test. Abbreviation: E, normal human mammary epithelium
placed into a recipient paraffin block using a tissue microar-
rayer (Beecher Instruments). Resulting microarray blocks
were used for immunohistochemical analysis. The sections
were stained using anti-CD26 and -α-SMA antibody accord-
ing to the conditions described in the immunohistochemistry
section. Immunohistochemical scores for CD26 and α-SMA
expressions in stromal fibroblast-like cells were determined
by a researcher with no prior knowledge of the clinicopatho-
logical results, as follows: negative and negligible (<10% of
total area) and moderately and significantly positive (more
than 10% of total area) for CD26 staining, and weakly posi-
tive (<50% of total area) and strongly positive (more than
50% of total area) for α-SMA staining.

2.4 | Statistical analysis

$P < 0.05$ was considered to indicate a statistically significant
difference, as indicated by * in graphs. When the $P$-value
was $< 0.001$, it was indicated as **. To investigate the asso-
ciations of stromal CD26 expression with patient characteris-
tics in stromal α-SMA-positive breast cancer, Fisher's exact
test was performed.

3 | RESULTS

3.1 | Attenuated CD26 expression on
stromal myofibroblasts in human breast
carcinomas

To examine whether stromal CD26 expression is attenu-
ated in human breast carcinomas, paraffin sections were
prepared from human breast cancer specimens and stained
with anti-CD26 or -α-SMA antibody. Few CD26-positive
cells were detected in tumor stroma including an abundance
of α-SMA-positive myofibroblasts, while a larger number of
CD26-positive fibroblast-like cells were present in a noncan-
cerous region lacking myofibroblasts of the breast far from
the outer tumor margin (Figure 1A). A subset of lymphocytes
also stained positive for CD26 (Figure S1A), while vascu-
lar endothelial cells were negative for CD26 (Figure S1B).
Moreover, most breast cancer cells stained negative for CD26
(Figure 1A), consistent with previous reports.20,21

To address whether CD26 expression is attenuated on stromal myofibroblasts in human breast tumors, double im-
munofluorescence was performed using both anti-CD26 and
-α-SMA antibodies. CD26 expression was barely detected on
α-SMA-positive myofibroblasts in tumor-associated stroma
(Figure 1B). In sharp contrast, considerable CD26 expres-
sion was observed in α-SMA-negative stromal fibroblasts
expressing vimentin, a marker of the mesenchymal cell type
in noncancerous regions (Figure 1B,C).

To extend this observation, we performed immunohisto-
chemistry on specimens from 10 patients in total (Table 1).
Of note, in all of the examined breast cancer patients, CD26-
positive fibroblast-like cell proportions were significantly de-
creased in the tumor-associated stroma as compared to those
in the corresponding noncancerous stroma of the same breast
(Figure 1D). Furthermore, we investigated another patient
cohort including 239 breast cancers by immunohistochemis-
try using anti-CD26 and -α-SMA antibodies. Stromal myofi-
brastos were stained positive for α-SMA in 193 out of 239
(80.8%) tumors. Stromal CD26 staining was also negative
or negligible (<10% positive) in 118 out of the 193 (61.1%)
tumors including stromal myofibroblasts, and showed no sig-
nificant correlations with any pathological parameters (Table
2). This decreased stromal CD26 staining tended to be asso-
ciated with poorer outcomes for breast cancer patients with
tumors rich in stromal myofibroblasts than did moderately

**Table 1** Patients' information

| Case | Sex | Age | Histology         | Histological grade | ER  | PR  | HER2 | Stage |
|------|-----|-----|-------------------|--------------------|-----|-----|------|-------|
| 1    | F   | 40  | IDC and DCIS      | 2                  | 90% | 90% | 2+   | IIB   |
| 2    | F   | 47  | IDC and DCIS      | 2                  | −   | −   | 1+   | IA    |
| 3    | F   | 75  | IDC and DCIS      | 3                  | −   | −   | 3+   | IIB   |
| 4    | F   | 61  | IDC and DCIS      | 2                  | −   | −   | 1+   | IIB   |
| 5    | F   | 55  | IDC and DCIS      | 2                  | >90%| >70%| 2+   | IA    |
| 6    | F   | 44  | IDC              | 2                  | >90%| >80%| 2+   | IA    |
| 7    | F   | 72  | IDC and DCIS      | 3                  | −   | −   | 1+   | IIA   |
| 8    | F   | 53  | IDC and DCIS      | 1                  | >90%| >90%| 2+   | IA    |
| 9    | F   | 76  | IDC and DCIS      | 3                  | −   | −   | 1+   | IA    |
| 10   | F   | 39  | IDC and DCIS      | 2                  | >90%| >90%| 2+   | IIB   |

*Note:* Information about patients whose breast tumor-derived FFPE tissue was used in this study for immunohistochemistry: diagnosis was performed by pathologists
in the Juntendo University Hospital.22-24 ER and PR positive cell number (%) and immunoreactivity of HER2 were determined according to ASCO guidelines.23,24
Stage was determined according to UICC TNM classification.

Abbreviations: −, negative; DCIS, ductal carcinoma in situ; ER, estrogen receptor; F, female; FFPE, formalin-fixed paraffin-embedded; HER2, human epithelial
growth factor receptor type 2; IDC, invasive ductal carcinoma; PR, progesterone receptor.
and significantly positive stromal CD26 staining (Figure 1E). Collectively, these data indicate that the attenuated CD26 expression on stromal myofibroblasts in tumors may contribute to poor outcomes in breast cancer patients.

### 3.2 Decreased CD26 expression on tumor-promoting human breast CAFs

As CD26 expression was attenuated on stromal myofibroblasts in human breast carcinomas, we investigated whether CD26 expression is also downregulated in primary cultured CAFs extracted from human breast carcinomas, compared to the corresponding control fibroblasts isolated from the adjacent non-cancerous tissues in same patients using public gene expression data. A significantly lower level of CD26 mRNA expression was detected in myofibroblastic CAFs that presumably acquired TGF-β and SDF-1 autocrine signaling, as exemplified by increased TGF-β2 and SDF-1 mRNA expression (Figure 2A). We also employed exp-CAF2 cells raised from immortalized human mammary fibroblasts that had been incubated with MCF-7-ras breast cancer cells in the tumor xenograft and then extracted from the developing tumor for subsequent expansion in culture. As mentioned above, the exp-CAF2 cells increasingly acquired myofibroblastic and tumor-promoting traits via establishment of TGF-β and SDF-1 autocrine signaling through interaction with carcinoma cells during tumor progression. We indeed found CD26 mRNA expression to be downregulated in exp-CAF2 cells, by 74.4% as compared to the control human mammary fibroblasts that were minimally activated, in terms of myofibroblastic and tumor-promoting properties (Figure 2B). Moreover, cell surface CD26 expression was decreased on exp-CAF2 cells by 64.7%, as demonstrated by flow cytometry (Figure 2C). In addition, CD26 protein expression and DPP-4 activity (CD26 peptidase activity) were decreased in exp-CAF2 cells by 73.0% and 78.2%, respectively (Figure 2D,E). Taken together, these findings indicate that CD26 expression and DPP-4 activity are significantly attenuated on myofibroblastic CAFs with activated TGF-β and SDF-1 autocrine signaling.

### 3.3 CD26 expression attenuated by TGF-β-Smad2/3 autocrine signaling on CAFs

We next investigated how CD26 expression is downregulated on CAFs. Given the increasingly activated TGF-β- and SDF-1-autocrine signaling in exp-CAF2 cells during tumor progression, we reasoned that such signaling might contribute to attenuation of CD26 expression on these cells. To examine this possibility, exp-CAF2 cells were treated with SB431542, an inhibitor for TGF-β receptor I kinase activity, which is crucial for phosphorylation of the downstream proteins represented by Smad2/3. CD26 expression was significantly upregulated at both the mRNA and protein levels on the resulting exp-CAF2 cells relative to the effect of control dimethyl sulfoxide treatment (Figure 3A-C). We also sought to the determine roles of the canonical TGF-β-Smad2/3 pathway in the attenuated CD26 expression on CAFs. To this end, we generated two different shRNA constructs against Smad4, which is a central mediator of the Smad2/3 signaling to inhibit Smad4 expression in exp-CAF2 cells. Inhibition of Smad4 expression by shRNA upregulated CD26 mRNA and protein expressions significantly more than

---

### TABLE 2

| Parameters         | Total n = 193 | Stromal CD26 negative and negligible staining (up to 10%) n = 118 | Stromal CD26 moderate and significant staining (more than 10%) n = 75 | P-value |
|--------------------|--------------|---------------------------------------------------------------|---------------------------------------------------------------|---------|
| Age (years)        | ~65          | 148                                                          | 96                                                           | 52      | 0.0576 |
|                    | 66~          | 45                                                           | 22                                                           | 23      |         |
| Grading            | 0            | 25                                                           | 15                                                           | 10      | 0.7677 |
|                    | 1            | 66                                                           | 42                                                           | 24      |         |
|                    | 2            | 53                                                           | 35                                                           | 18      |         |
|                    | 3            | 49                                                           | 26                                                           | 23      |         |
| pT factor          | T1           | 74                                                           | 44                                                           | 30      | 0.762  |
|                    | T2-3         | 119                                                          | 74                                                           | 45      |         |
| pN factor          | N0           | 102                                                          | 58                                                           | 44      | 0.237  |
|                    | N1-2         | 91                                                           | 60                                                           | 31      |         |
| ER                 | Positive     | 135                                                          | 89                                                           | 46      | 0.0527 |
|                    | Negative     | 58                                                           | 29                                                           | 29      |         |
| HER2               | Positive     | 28                                                           | 16                                                           | 12      | 0.678  |
|                    | Negative     | 165                                                          | 102                                                          | 64      |         |

Abbreviations: ER, estrogen receptor; HER2, human epithelial growth factor receptor type 2.
did the GFP-shRNA (Figure 3D-F). In sharp contrast, the expression level of phosphorylated Smad2 (pSmad2), indicative of the activation of TGF-β signaling, was strongly attenuated in exp-CAF2 cells expressing Smad4-shRNA (Figure 3F). These data therefore indicate that the TGF-β-Smad2/3 signaling pathway is required for maintenance of the attenuated CD26 expression on CAFs.

Given the TGF-β-Smad2/3 signaling requirement for the attenuated CD26 expression on CAFs, we also investigated whether this signaling suffices to induce downregulation of CD26 expression. To examine this possibility, human mammary fibroblasts were treated with TGF-β1. Expression levels of CD26 mRNA and protein were significantly attenuated in these cells (Figure 3G-I). Taken together, these findings demonstrate that activation of TGF-β-Smad2/3 signaling induces and maintains the attenuated CD26 expression on exp-CAF2 cells.

### 3.4 SDF-1 signaling and CD26 expression on CAFs

Since SDF-1 signaling is critical for mediating the myofibroblastic tumor-promoting trait in CAFs, we investigated whether this signaling regulates CD26 expression on these cells.

To assess this possibility, CD26 expression was measured on exp-CAF2 cells expressing SDF-1-shRNAs, both of which significantly inhibited SDF-1 expression (Figure S2A). Inhibition of SDF-1 expression upregulated levels of CD26 protein expression on these cells as compared to the effect of GFP-shRNA, as demonstrated by flow cytometry (Figure 4A) and Western blotting (Figure 4B). Furthermore, pSmad2 expression was also attenuated in exp-CAF2 cells expressing each of these SDF-1-shRNAs (Figure 4B). These findings therefore indicate that SDF-1 expression is required for the attenuation of CD26 expression via activation of Smad2/3 signaling on exp-CAF2 cells. This observation is consistent with our previous findings, indicating that SDF-1 signaling mediates TGF-β-Smad2/3 signaling in CAFs.

We next examined whether SDF-1-CXCR4 signaling suffices to attenuate the CD26 expression on mammary fibroblasts. To answer this question, a retroviral construct encoding either human SDF-1 or CXCR4 cDNA was introduced into human mammary fibroblasts (Figure S2B). The levels of CD26 protein expression were similar in parental human mammary fibroblasts and...
those overexpressing SDF-1 or CXCR4, as demonstrated by flow cytometry (Figure 4C) and Western blotting (Figure 4D). pSmad2 expressions also differed minimally among all of these fibroblasts (Figure 4D). Conversely, CD26 expression was robustly inhibited on human mammary fibroblasts expressing an active TGF-β1 cDNA via increased pSmad2 expression (Figures 4D and S2B), confirming earlier data showing attenuated CD26 expression on the TGF-β1-treated mammary fibroblasts (Figure 3I).

Collectively, these findings indicate that SDF-1 autocrine signaling is required for maintenance of the attenuated CD26 expression on carcinoma-associated fibroblasts (CAFs).
expression on CAFs presumably via Smad2/3 signaling, but is not sufficient for inducing the downregulation of CD26 expression on these cells (Figure 4E). As mentioned above, the activation of TGF-β-Smad2/3 signaling was found to both induce and maintain the downregulated CD26 expression on CAFs (Figure 4E).

3.5 | Roles of decreased DPP-4 activity on CAFs in TGF-β and SDF-1 autocrine signaling

SDF-1 is a major substrate for CD26/DPP-4 peptidase.14,29 The resulting failure of transduction of the downstream signaling of CXCR4, an SDF-1 receptor present on the target cells, attenuates hematopoietic stem/progenitor cell homing,30 HIV infection,31,32 and cancer cell invasion.33-36 Given these observations, we speculated that the attenuated stromal CD26 expression may influence SDF-1 autocrine signaling and the myofibroblastic state in CAFs. To this end, a retroviral vector encoding the human CD26 cDNA or the corresponding control empty vector was introduced into exp-CAF2 cells or control fibroblasts. CD26 protein expression and DPP-4 activity were markedly increased on exp-CAF2 cells expressing CD26 (exp-CAF2-CD26) as compared to the control vector (exp-CAF2-empty) (Figure 5A,B). However, TGF-β and SDF-1 autocrine signaling as well as the myofibroblastic trait, as exemplified by TGF-β1, TGF-β2, pSmad2, SDF-1, and α-SMA expressions were similar in these cells (Figure 5C,D). These data therefore indicate that the attenuated CD26 expression does not significantly contribute to activation of TGF-β and SDF-1 autocrine signaling or to the myofibroblastic trait in CAFs.

3.6 | Roles of attenuated DPP-4 activity on CAFs in their SDF-1 paracrine signaling toward apposed carcinoma cells

We have previously demonstrated that CAF-produced SDF-1 promotes the growth of nearby breast tumor cells in a paracrine fashion via acting through CXCR4 on these cells.10 We thus speculated that decreased levels of membrane and soluble CD26 expressions on CAFs may promote paracrine SDF-1 signaling toward nearby carcinoma cells.

To investigate this possibility, the biological activity of stromal SDF-1 was evaluated employing the Boyden chamber cell migration assay using human breast cancer MDA-MB-231 cells and DCIS cells overexpressing CXCR4 (DCIS-CXCR4) (Figure 5E). We observed more

FIGURE 4 Stromal cell-derived factor-1 (SDF-1) autocrine signaling required for the attenuated CD26 expression on exp-carcinoma-associated fibroblasts (CAFs) cells. A, Flow cytometry of indicated cells using anti-CD26 antibody (red line) or the control IgG (black line). The number of CD26-positive cell populations (%) is also depicted. B, Western blotting of exp-CAF2 cells expressing the indicated shRNA. The ratio of the signal intensity of CD26 relative to α-tubulin is indicated. C, Flow cytometry of human normal mammary fibroblasts (parental, black line) expressing SDF-1 (red line) or CXCR4 (green line) cDNA construct using anti-CD26 antibody (solid line) or the control IgG (dotted line). D, Western blotting of human normal mammary fibroblasts expressing the indicated cDNA construct. E, Schematic representation of the attenuated CD26 expression via transforming growth factor-β (TGF-β)-Smad2/3 and SDF-1 autocrine signaling on human breast CAF myofibroblasts. TGF-β released from tumor cells and stromal cells attenuates CD26 expression on human mammary fibroblasts. Acquisition of TGF-β and SDF-1 autocrine signaling pathways then contributes to maintenance of the attenuated CD26 expression on CAFs during tumor progression.
robust migration of these cancer cells to be induced by the SDF-1-rich medium conditioned by exp-CAF2-empty relative to control fibroblast-empty (Figure 5F,G). Medium derived from exp-CAF2-CD26 or exp-CAF2-empty cells, when applied to these cancer cells, showed similar tumor cell migration (Figure 5F,G). Furthermore, SDF-1 protein concentrations were similar in media conditioned by these cells (Figure 5H). Moreover, DPP-4 activity was nearly undetectable in media obtained from exp-CAF2-CD26 and control human mammary fibroblasts abundantly expressing CD26 (Figure 5I), while a markedly higher level of DPP-4 activity was detected in the whole cell lysate extracted from these fibroblasts (Figure 5B). Collectively, these observations indicate that membrane CD26 is barely shed on exp-CAF2-CD26 and human mammary fibroblasts, suggesting that increased membrane CD26 expression by itself may not be enough to inhibit the SDF-1 activity. However, whether attenuated soluble CD26 production promotes paracrine SDF-1 signaling from CAFs could not be resolved by the experiments above.

**FIGURE 5** Attenuated CD26 expression is not essential for stromal cell-derived factor-1 (SDF-1)-autocrine and -paracrine signaling in carcinoma-associated fibroblasts (CAFs). A, Flow cytometry of exp-CAF2-empty (black line) or -CD26 (red line) cells using anti-CD26 antibody (solid line) or the control IgG (dotted line). The number of CD26-positive cell populations (%) is shown. B, Dipeptidyl peptidase-4 (DPP-4) activity in the indicated fibroblasts (n = 3). C, Real-time PCR of indicated cells for transforming growth factor-β1 (TGF-β1), TGF-β2, SDF-1 and α-SMA expressions. D,E, Western blotting of the indicated cells. F,G, Boyden chamber cell migration assay of DCIS-CXCR4 cells (F) or MDA-MB-231 cells (G) using conditioned medium (CM) taken from the indicated cells. The cells which had migrated were stained with May-Grünwald Giemsa at 60 h (DCIS-CXCR4, F) or at 12 h (MDA-MB231, G) after the cell seeding. Scale bar, 300 μm. The number of tumor cells which migrated per field is shown (n = 3). H, ELISA of CM taken from the indicated fibroblasts (2.5 × 10⁵ or 5 × 10⁵ cells) for measuring SDF-1. I, DPP-4 activity in CM derived from the indicated fibroblasts (n = 3). **P < 0.001 and *P < 0.05 by Student’s t-test. Error bars, SE. Abbreviation: n.s., not significant.
4 | DISCUSSION

4.1 Attenuated CD26 expression in myofibroblastic CAFs is associated with poor outcomes in breast cancer patients

Stromal CD26 expression is known to be barely detectable in different human SCCs. However, whether stromal CD26 expression is also downregulated in human breast carcinomas remains controversial; stromal CD26 expression was reportedly undetectable in a tumor taken from one breast cancer patient, while its expression was detected in another human breast carcinoma. Moreover, particular stromal cell types potentially lacking CD26 expression in tumors and the molecular mechanisms underlying the decreased stromal CD26 expression have not as yet been fully elucidated.

In this study, we showed CD26 staining to be attenuated on myofibroblasts rich in tumor-associated stroma in specimens obtained from breast cancer patients. On the cultured human breast myofibroblastic CAFs, CD26 expression is also significantly attenuated relative to that on control human mammary fibroblasts. TGF-β and SDF-I autocrine signaling is responsible for the attenuated CD26 expression on these cells via Smad2/3 (Figure 4E). Given the induction of the attenuated CD26 expression on TGF-β-treated human mammary fibroblasts (Figure 3G-I), different sources of TGF-β derived from tumor cells and stromal cells in addition to CAFs may contribute to inducing downregulation of CD26 expression on mammary fibroblasts during tumor progression.

Distinct fibroblast populations with inherent functional diversity exist in stroma of human breast and skin tissues as well as various human tumors. CD26 expression has been demonstrated to serve as a marker for stratification of the stromal cell type in human breast and skin tissues. CD105/endoglin, a coreceptor for TGF-β family members, is also expressed on a subset of stromal myofibroblasts at the invasive borders of human colon carcinomas. Moreover, CD26<sup>low</sup>CD105<sup>high</sup> fibroblasts with myofibroblast-related characteristics are abundant in the terminal duct lobular unit of the human breast, while interlobular ducts are rich in CD26<sup>high</sup>CD105<sup>low</sup> fibroblasts. Collectively, these observations indicate the importance of CD26 and CD105 expressions for identifying the particular fibroblast lineages in human mammary tissues including those of breast cancer.

We demonstrated that the attenuated CD26 staining in tumor-associated stroma with an abundance of myofibroblasts is associated with poor outcomes for breast cancer patients, suggesting stromal CD26 staining to be a potentially novel prognostic marker. However, due to the lack of a statistically significant difference, we assume that use of another marker with stromal CD26 staining may improve prognostic power. As CD105 expression in CAFs has been indicated to mediate the activities of these fibroblasts, thereby promoting colon tumor invasion and metastasis, whether CD26<sup>low</sup>CD105<sup>high</sup> might serve as a valuable prognostic marker must be addressed in future studies.

Increased levels of stromal TGF-β and SDF-1 staining are also reported to be associated with the poor outcomes in breast cancer patients. Although these cytokines are highly produced by CAFs, as indicated earlier, it remains unclear whether CAF-derived TGF-β and SDF-1 in tumors contribute to poor prognoses via downregulated stromal CD26 expression in breast cancer patients.

4.2 CD26 shedding on stromal fibroblasts

Shedding of membrane CD26 has been widely recognized on various cell types, such as human adipocytes, vascular smooth muscle cells (VSMCs), and peripheral blood mononuclear cells (PBMCs). Several matrix metalloproteinases (MMPs) mediate the membrane CD26 shedding on adipocytes and VSMCs. Kallikrein-related peptidase 5 (KLK5) also plays roles in the shedding of CD26 on human PBMCs; the CD26 shedding from PBMCs is significantly inhibited by treatment with a KLK5 inhibitor, while treatment with recombinant KLK5 has the opposite effect, dramatically inducing CD26 shedding from CD4<sup>+</sup> T cells.

On the other hand, DPP-4 activity was barely detectable in media conditioned by human mammary fibroblasts and CAFs expressing a human CD26 cDNA construct. Various proteases, such as MMP2, MMP9, urokinase-type plasminogen activator, and cathepsins potentially regulating membrane CD26 shedding are likely to be detectable in these fibroblasts according to previous reports. We thus speculate that these proteases may not be responsible for CD26 shedding on human mammary fibroblasts.

4.3 Myofibroblastic CAFs and fibrosis-derived myofibroblasts show inverse CD26 expression pattern

Analogies between tumors and wound tissues have been portrayed as “tumors: wounds that do not heal,” based on their similar biological processes, as exemplified by the recruitment of large numbers of myofibroblasts, extracellular matrix deposition, tissue inflammation, and angiogenesis. These analogous processes are also further supported by gene expression profiles between tumor-associated stroma and tissue regeneration/repair responses.

CD26 expression has been shown to be significantly upregulated on stromal fibroblasts associated with wounds and fibrosis. Treatment with a DPP-4 inhibitor also attenuates the activated myofibroblastic states by inhibiting canonical TGF-β-Smad2/3 signaling as well as noncanonical ERK and p38 signaling. These findings suggest that CD26 expression is required for maintenance of the activated state
on myofibroblasts present in the damaged tissues via TGF-β signaling during regeneration and repair.

In sharp contrast, we observed significantly attenuated CD26 expression on stromal myofibroblasts in human breast carcinomas. Restoration of CD26 expression also has only a very minor influence on the TGF-β-Smad2/3 pathway in human breast CAFs (Figure 5C,D). Thus, this contrasting CD26 expression pattern and distinct actions modulating TGF-β signaling serve as an exception to the well-recognized analogies between wound-associated fibroblasts and CAFs. To further understand the biology of CAFs, molecular insights into the mechanisms underlying the cell-type specific roles of CD26 expression on these myofibroblasts are needed.

In summary, we obtained the unexpected findings that stromal CD26 expression is significantly attenuated through TGF-β and SDF-1 autocrine signaling on myofibroblastic CAFs in human breast carcinomas. As the attenuated CD26 expression in stromal myofibroblasts correlated with poor outcomes for breast cancer patients, decreased stromal CD26 expression may be useful as a prognostic marker for breast cancer patients.

ACKNOWLEDGMENTS

We thank Naomi Ohtsuji, Wali Nadila, and Katsumi Miyahara for assistance with the immunohistochemistry and HE staining. Masaaki Abe kindly instructed us in the flow cytometry analysis technique. We also thank Kazunori Kajino, Toshiyuki Kobayashi, Ryo Hatano, and Yasuhiko Ito for useful discussions. This work was supported by Grants in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (24300332, 25640069 and 15K14385 to A.O. and JP 16H06277 to Y.D.).

CONFLICT OF INTEREST

The authors have no potential conflict of interest to declare.

ORCID

Yoshihiro Mezawa https://orcid.org/0000-0002-2095-3867

Akira Orimo https://orcid.org/0000-0001-5330-7282

REFERENCES

1. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myo-fibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol. 2004;48:509-517.

2. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer. 2003;107:1-10.

3. Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839-849.

4. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582-598.

5. Mezawa Y, Orimo A. The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas. Cell Tissue Res. 2016;365:675-689.

6. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30:1002-1019.

7. Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211:1503-1523.

8. Colan A, Lonardo E, Berenguer-Llergo A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47:320-329.

9. Kojima Y, Acar A, Eaton EN, et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010;107:20009-20014.

10. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335-348.

11. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol. 2013;228:1651-1657.

12. Paulsson J, Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol. 2014;25:61-68.

13. Hu G, Xu F, Zhong K, Wang S, Huang L, Chen W. Activated tumor-infiltrating fibroblasts predict worse prognosis in breast cancer patients. J Cancer. 2018;9:3736-3742.

14. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol. 2003;82:53-73.

15. Klemann C, Wagner L, Stephan M, von Horsten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185:1-21.

16. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008;29:295-301.

17. Arwert EN, Mentink RA, Driskell RR, et al. Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation. Oncogene. 2012;31:992-1000.

18. Kacar A, Arikok AT, Kokenek Unal TD, Onder E, Hucumenoglu S, Alper M. Stromal expression of CD34, alpha-smooth muscle actin and CD26/DPPIV in squamous cell carcinoma of the skin: a comparative immunohistochemical study. Pathol Oncol Res. 2012;18:25-31.

19. Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008;56:43-53.

20. Atherton AJ, Monaghan P, Warburton MJ, Robertson D, Kenny AJ, Gusterson BA. Dipeptidyl peptidase IV expression identifies a functional sub-population of breast fibroblasts. Int J Cancer. 1992;50:15-19.

21. Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994;91:5657-5661.
22. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T. Establishment of histological criteria for high-risk node-negative breast carcinoma for a multifinstitutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. *Jpn J Clin Oncol*. 1998;28:486-491.

23. Wolff AC, Hammond M, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol*. 2007;25:118-145.

24. Hammond M, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol*. 2010;28:2784-2795.

25. Bauer M, Su G, Casper C, He R, Rehrauer W, Friedl A. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. *Oncogene*. 2010;29:1732-1740.

26. Scherz-Shouval R, Santagata S, Mendillo M, et al. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. *Cell*. 2014;158:564-578.

27. Polanska UM, Acar A, Orimo A. Experimental generation of carcinoma-associated fibroblasts (CAFs) from human mammary fibroblasts. *J Vis Exp*. 2011;e3201.

28. Derynck R, Miyazono K. *The Biology of the TGF-beta Family*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2017.

29. Lambeir A-M, Proost P, Durinx C, et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. *J Biol Chem*. 2001;276:29839-29845.

30. Christopherson KW 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. *Science*. 2004;305:1000-1003.

31. Ohtsuki T, Hosono O, Kobayashi H, et al. Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1alpha by CD26/dipeptidyl peptidase IV. *FEBS Lett*. 1998;431:236-240.

32. Shioda T, Kato H, Ohnishi Y, et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. *Proc Natl Acad Sci U S A*. 1998;95:6331-6336.

33. Sun Y-X, Pedersen EA, Shiozawa Y, et al. CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. *Clin Exp Metastasis*. 2008;25:765-776.

34. Mizokami Y, Kajiyama H, Shibata K, Ino K, Kikkawa F, Mizutani S. Stromal cell-derived factor-1alpha-induced cell proliferation and its possible regulation by CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma. *Int J Cancer*. 2004;110:652-659.

35. Cutler MJ, Lowthers EL, Richard CL, Hajducek DM, Spagnuolo PA, Blay J. Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCXR4-negative cells and increasing peptidase CD26. *BMC Cancer*. 2015;15:882.

36. Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. Possible involvement of SDF-1alpha/CXCR4-DPP4IV axis in TGF-beta1-induced enhancement of migratory potential in human peritoneal mesothelial cells. *Cell Tissue Res*. 2007;330:221-229.

37. Walker RA, Dearing SJ. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. *Eur J Cancer*. 1992;28:641-644.

38. Morsing M, Klitgaard MC, Jafari A, et al. Evidence of two distinct functionally specialized fibroblast lineages in breast stroma. *Breast Cancer Res*. 2016;18:108.

39. Driksell RR, Lichtenberger BM, Hoste E, et al. Distinct fibroblast lineages determine dermal architecture in skin development and repair. *Nature*. 2013;504:277-281.

40. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. Anatomic demarcation by positional variation in fibroblast gene expression programs. *PLoS Genet*. 2006;2:e119.

41. Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast Heterogeneity and Immunosuppressive environment in human breast cancer. *Cancer Cell*. 2018;33:463-479.

42. Ohlund D, Handly-Santana A, Biiifi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *J Exp Med*. 2017;214:579-596.

43. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. *Cancer Biol Ther*. 2006;5:1640-1646.

44. Atherton AJ, O’Hare MJ, Buluwela L, et al. Ectoenzyme regulation by phenotypically distinct fibroblast sub-populations isolated from the human mammary gland. *J Cell Sci*. 1994;107(Pt 10):2931-2939.

45. Pauwwe M, Schoonderwoerd M, Helderman RF, et al. Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis. *Clin Cancer Res*. 2018;24:6331-6344.

46. Richardsen E, Uglehbus RD, Johnsen SH, Busund LT. Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. *BMC Res Notes*. 2012;5:110.

47. Ahirwar DK, Nasser MW, Ouseph MM, et al. Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation. *Oncogene*. 2018;37:4428-4442.

48. Rohrborn D, Eckel J, Sell H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. *FEBS Lett*. 2014;588:3870-3877.

49. Nargis T, Kumar K, Ghosh AR, et al. KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes. *Mol Metab*. 2017;6:1529-1539.

50. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. *Clin Exp Metastasis*. 2007;24:647-656.

51. Kleer CG, Bloushat-Jimron N, Chen Y-H, et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. *Clin Cancer Res*. 2008;14:5357-5367.

52. Stuelten CH, DaCosta BS, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. *J Cell Sci*. 2005;118:2143-2153.

53. Sieuwerts AM, Klijn JG, Henzen-Logmand SC, et al. Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta1 (TGF beta1) compared with factor(s) released by human epithelial-carcinoma cells. *Int J Cancer*. 1998;76:829-835.
54. Foster DS, Jones RE, Ransom RC, Longaker MT, Norton JA. The evolving relationship of wound healing and tumor stroma. *JCI Insight*. 2018;3 pii: 99911.

55. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. *Nat Rev Mol Cell Biol*. 2008;9:628-638.

56. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N Engl J Med*. 1986;315:1650-1659.

57. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. *PLoS Biol*. 2004;2:E7.

58. Pedersen TX, Leethanakul C, Patel V, et al. Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. *Oncogene*. 2003;22:3964-3976.

59. Riss J, Khanna C, Koo S, et al. Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. *Cancer Res*. 2006;66:7216-7224.

60. Min HS, Kim JE, Lee MH, et al. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. *Lab Invest*. 2014;94:598-607.

61. Hong SK, Choo EH, Ihm SH, Chang K, Seung KB. Dipeptidyl peptidase 4 inhibitor attenuates obesity-induced myocardial fibrosis by inhibiting transforming growth factor-beta1 and Smad2/3 pathways in high-fat diet-induced obesity rat model. *Metabolism*. 2017;76:42-55.

62. Kaji K, Yoshiji H, Ikenaka Y, et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. *J Gastroenterol*. 2014;49:481-491.

63. Shi S, Srivastava SP, Kanasaki M, et al. Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. *Kidney Int*. 2015;88:479-489.

64. Thielitz A, Vetter RW, Schulze B, et al. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. *J Invest Dermatol*. 2008;128:855-866.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

---

**How to cite this article**: Mezawa Y, Daigo Y, Takano A, et al. CD26 expression is attenuated by TGF-β and SDF-1 autocrine signaling on stromal myofibroblasts in human breast cancers. *Cancer Med*. 2019;8:3936–3948. [https://doi.org/10.1002/cam4.2249](https://doi.org/10.1002/cam4.2249)